FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Cormack Scott Daniel
   2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ACHV] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
19820 NORTH CREEK PARKWAY, SUITE 201		 3. Date of Earliest Transaction (Month/Day/Year)
08/01/2017
(Street)

BOTHELL, WA 98011		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2017   M   3,125 (1) A $ 0 16,302 D  
Common Stock 08/01/2017   M   1,590 (1) A $ 0 9,685 I By Spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU) (2) 08/01/2017   M     568   (3) 04/13/2018 Common Stock 568 (4) $ 0 0 D  
Restricted Stock Unit (RSU) (2) 08/01/2017   M     1,705   (3) 06/18/2019 Common Stock 1,705 (4) $ 0 0 D  
Restricted Stock Unit (RSU) (2) 08/01/2017   M     852   (3) 06/12/2018 Common Stock 852 (4) $ 0 0 D  
Restricted Stock Unit (RSU) (2) 08/01/2017   M     284   (5) 04/13/2018 Common Stock 284 (4) $ 0 0 I By Spouse
Restricted Stock Unit (RSU) (2) 08/01/2017   M     852   (5) 06/18/2019 Common Stock 852 (4) $ 0 0 I By Spouse
Restricted Stock Unit (RSU) (2) 08/01/2017   M     454   (5) 06/12/2018 Common Stock 454 (4) $ 0 0 I By Spouse
Stock Option (right to buy) $ 4.57 08/01/2017   A   11,000   08/01/2018 08/01/2027 Common Stock 11,000 $ 0 11,000 D  
Stock Option (right to buy) $ 245.08 (4)               (3) 12/31/2019 Common Stock 2,272 (4)   2,272 D  
Stock Option (right to buy) $ 175.67 (4)               (3) 12/14/2020 Common Stock 3,636 (4)   3,636 D  
Stock Option (right to buy) $ 143 (4)               (3) 05/08/2022 Common Stock 3,409 (4)   3,409 D  
Stock Option (right to buy) $ 131.45 (4)               (3) 03/12/2023 Common Stock 3,409 (4)   3,409 D  
Stock Option (right to buy) $ 129.69 (4)               (3) 03/14/2024 Common Stock 4,545 (4)   4,545 D  
Stock Option (right to buy) $ 20.46 (4)               (3) 05/19/2025 Common Stock 6,818 (4)   6,818 D  
Stock Option (right to buy) $ 156.2 (4)               (5) 06/08/2020 Common Stock 318 (4)   318 I By Spouse
Stock Option (right to buy) $ 185.13 (4)               (5) 01/03/2021 Common Stock 3,181 (4)   3,181 I By Spouse
Stock Option (right to buy) $ 143 (4)               (5) 05/08/2022 Common Stock 1,363 (4)   1,363 I By Spouse
Stock Option (right to buy) $ 131.45 (4)               (5) 03/12/2023 Common Stock 1,818 (4)   1,818 I By Spouse
Stock Option (right to buy) $ 129.69 (4)               (4) 03/14/2024 Common Stock 2,272 (4)   2,272 I By Spouse
Stock Option (right to buy) $ 20.46 (4)               (5) 05/19/2015 Common Stock 3,409 (4)   3,409 I By Spouse

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Cormack Scott Daniel
19820 NORTH CREEK PARKWAY
SUITE 201
BOTHELL, WA 98011		   X      

Signatures

 Sandra Thomson as attorney-in-fact for Scott Cormack   08/03/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. On August 1, 2017, the effective date of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. (the "Merger"), the closing price of Achieve Life Sciences, Inc.'s common stock was $4.576 per share, representing a closing price of $0.416 per share of Oncogenex common stock as adjusted to reflect an 11-to-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
(2) Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.
(3) Pursuant to the terms of the reporting holder's employment agreement, the RSUs immediately vested in full on August 1, 2017, in connection with the consummation of the Merger.
(4) Reflects the Reverse Stock Split.
(5) Pursuant to the terms of the reporting holder's spouse's consulting agreement, the RSU immediately vested on August 1, 2017, in connection with the consummation of the Merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.